Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Multiple Myeloma 6Neoplasms 5Neoplasm Metastasis 3Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Leukemia 2Kidney Neoplasms 2Carcinoma, Renal Cell 2Vomiting 1Stomatitis 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Alveolar Soft Part 1Renal Insufficiency 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Paraproteinemias 1Oncology Patients Receiving Chemotherapy 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasm, Residual 1Nausea 1NSCLC 1Mucositis 1Mastocytosis, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1

Interventions

cediranib 3perifosine 2pembrolizumab 2pazopanib 2atezolizumab 2Sunitinib 2Specimen Handling 2Loperamide 2selinexor 1sargramostim 1romidepsin 1cabozantinib 1brostallicin 1atropine sulfate-diphenoxylate hydrochloride drug combination 1Warfarin 1Vitamin B 6 1Trabectedin 1Thyroxine 1Temozolomide 1Radiotherapy, Intensity-Modulated 1Radiation Dose Hypofractionation 1Pyridoxine 1Promethazine 1Prochlorperazine 1Polymerase Chain Reaction 1Petrolatum 1Neoadjuvant Therapy 1Mass Spectrometry 1Lorazepam 1Immunoglobulin G 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Sarcoma, Alveolar Soft Part × Diphenhydramine × Clear all
NCT01391962 2026-02-02

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
34 enrolled 22 charts
Sarcoma

Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡